ArticleMaterials today. Bio2026
A study on extracellular and cellular composition to advance towards the rational design of contractile human myocardium.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recapitulation of the physiological cellular composition, 3D structure and mechanics of the human myocardium is key to improving the biofabrication of cardiac tissues. To advance the development of engineered heart patches, with significant potential for human cardiac repair, we assessed the impact of their cellular and extracellular constituents on tissue organization and function, by using advanced biofabrication and next-generation sequencing technologies. Combining melt electrowriting (MEW) fibrillary scaffolds with human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (hiPSC-CMs) and cardiac fibroblasts (-CFs), we generated human engineered cardiac tissues (MEW-hECTs) by casting in two different biomaterial compositions (fibrin and gelatin-methacryloyl (GelMA)), and varying proportions of the cardiac constituent cells. Under the conditions tested, fibrin-hECTs displayed improved tissue formation, coordinated contraction, structural organization, and electrophysiological behavior compared with GelMA-hECTs. Transcriptomics analysis indicated that fibrin-hECTs exhibited an increase in maturation-associated gene expression signatures compared with GelMA-hECTs, whereas a longer remodeling process of the synthetic environment was required in GelMA. Surprisingly, within the investigated MEW-based composite system, the inclusion of CFs had no positive impact on tissue organization and impaired the electrophysiological properties of myocardial constructs, increasing susceptibility to arrhythmias in computational simulations calibrated with experimental electrophysiological data. This information will help devise advanced myocardial tissues by enabling a comprehensive assessment of the main components, ultimately reflecting the unique native cardiac 3D organization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.